Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 5/14/2017
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||AHPVA143DA / 2||LA / IM|
Administered by: Other Purchased by: Other
Symptoms: Asthenia, Motor dysfunction
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? No
Other Medications: No other medications
Current Illness: Unknown
Diagnostic Lab Data:
CDC 'Split Type': JP2015JPN178875
Write-up:This case was reported by a physician via sales rep and described the occurrence of motor dysfunction in a 20-year-old female subject who received CERVARIX (batch number AHPVA122BA, expiry date unknown), (batch number AHPVA100CA, expiry date unknown) and (batch number AHPVA143DA, expiry date unknown). On 19th March 2011, the subject received the 1st dose of CERVARIX (intramuscular) .5 ml. On 23rd April 2011, the 2nd dose was .5 ml. On 5th October 2011, the 3rd dose was .5 ml. On an unknown date, unknown after receiving CERVARIX, the subject experienced motor dysfunction (serious criteria disability) and weakness generalised (serious criteria disability). On an unknown date, the outcome of the motor dysfunction and weakness generalised were unknown. It was not reported if the reporter considered the motor dysfunction and weakness generalised to be related to CERVARIX.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166